ABBV Jan 2024 120.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:08AM EDT. Market open.
| Previous close | 0.5700 |
| Open | 0.5700 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 120.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.5700 - 0.5700 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.76k |
Simply Wall St.AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 57% Above Its Share Price
Key Insights AbbVie's estimated fair value is US$243 based on 2 Stage Free Cash Flow to Equity Current share price of...
ZacksAbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
AbbVie (ABBV) closed at $154.65 in the latest trading session, marking a +1.25% move from the prior day.
PR NewswireAbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Union (EU), as well as Liechtenste
© 2023 Yahoo. All rights reserved.
